Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10307799 | 0.89 | MAPT (0.46) | ALDH1A1FOLH1CYP2C19ATMSMN1; SMN2 | |
| SCHEMBL17381367 | 0.85 | CYP2C19 (0.49) | ALDH1A1PPARGPPARACYP2C19POLB | |
| SCHEMBL15468643 | 0.84 | FOLH1 (0.38) | FOLH1PPARGPPARACYP2C19TRPA1 | |
| SCHEMBL22299026 | 0.84 | CYP2C19 (0.48) | ALDH1A1PPARGPPARACYP2C19TRPA1 | |
| SCHEMBL14027337 | 0.81 | ALDH1A1 (0.38) | ALDH1A1PPARGPPARACYP2C19TRPA1 | |
| SCHEMBL14027322 | 0.77 | ALDH1A1 (0.40) | ALDH1A1PPARGPPARACYP2C19TRPA1 | |
| SCHEMBL17973796 | 0.77 | CYP2C19 (0.43) | ALDH1A1CYP2C19POLBSMN1; SMN2 | |
| SCHEMBL16282701 | 0.77 | ALDH1A1 (0.49) | ALDH1A1CYP2C19TRPA1SMN1; SMN2TRPV1 | |
| SCHEMBL3713575 | 0.75 | MAPT (0.47) | ALDH1A1PPARGPPARACYP2C19ATM | |
| SCHEMBL10454113 | 0.75 | CYP2C19 (0.46) | ALDH1A1FOLH1CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785475-B2 | Lipoic acid derivatives | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20080262034-A1 | selectively kill tumor cells by altering cancer cell metabolism and signal transduction pathways linked to the Warburg Effect; | CORNERSTONE PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262034-A1 | selectively kill tumor cells by altering cancer cell metabolism and signal transduction pathways linked to the Warburg Effect; | DLD, SLC25A1, PDK2 | ALDH1A1 745/4885FOLH1 1777/4885PPARG 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.